SCHEMBL4194367

SCHEMBL4194367

CC(=O)[C@@H](Oc1ccc2c(c1)c(C(=O)CC(C)(C)C)c(CC(C)(C)C(=O)O)n2Cc1ccc(Cl)cc1)C1CCCN1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGES2 Q9H7Z7 6/20 0.59
PTGES O14684 2/20 0.59
PTGS1 P23219 1/20 0.55
PTGS2 P35354 1/20 0.55
ALOX5AP P20292 13/20 0.49
ALOX5 P09917 1/20 0.45
KDM4E B2RXH2 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
HIF1A Q16665 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4187977 0.88 ALOX5AP (0.57) PTGES2PTGESALOX5APKDM4ECYP1A2
SCHEMBL502931 0.87 ALOX5AP (0.63) PTGES2PTGESPTGS2ALOX5APALOX5
SCHEMBL3467197 0.87 ALOX5AP (0.63) PTGES2PTGESPTGS2ALOX5APALOX5
SCHEMBL3468547 0.84 ALOX5AP (0.57) PTGES2PTGESPTGS1PTGS2ALOX5AP
SCHEMBL3462049 0.82 ALOX5AP (0.54) PTGES2ALOX5APKDM4ECYP1A2CYP3A4
SCHEMBL4203818 0.81 ALOX5AP (0.63) PTGES2PTGESPTGS2ALOX5APALOX5
SCHEMBL23270793 0.80 PTGES2 (0.73) PTGES2PTGESPTGS1PTGS2ALOX5AP
SCHEMBL30181215 0.80 PTGES2 (0.73) PTGES2PTGESPTGS1PTGS2ALOX5AP
SCHEMBL3049682 0.80 ALOX5AP (0.63) PTGES2PTGESPTGS2ALOX5APALOX5
SCHEMBL3462819 0.80 ALOX5AP (0.62) PTGES2PTGESPTGS2ALOX5APALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841295-B2 5-lipoxygenase-activating protein (FLAP) inhibitors PANMIRA PHARMACEUTICALS, LLC (US) 2014-09-23 US claimed
US-20090221574-A1 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors AMIRA PHARMACEUTICALS, INC. (US) 2009-09-03 US claimed
EP-1942896-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS Amira Pharmaceuticals, Inc. (US) 2008-07-16 EP claimed
WO-2007056220-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-18 WO claimed
US-8841295-B2 5-lipoxygenase-activating protein (FLAP) inhibitors PANMIRA PHARMACEUTICALS, LLC (US) 2014-09-23 US disclosed
US-20090221574-A1 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors AMIRA PHARMACEUTICALS, INC. (US) 2009-09-03 US disclosed
EP-1942896-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS Amira Pharmaceuticals, Inc. (US) 2008-07-16 EP disclosed
US-20070219206-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-09-20 US disclosed
WO-2007056220-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221574-A1 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors ALOX5, ALOX15B, ALOX15 PTGES2 29/4885PTGES 15/4885PTGS1 27/4885
US-20070219206-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 PTGES2 29/4885PTGES 15/4885PTGS1 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.